Cited 0 times in Scipus Cited Count

Twelve-Month Efficacy of Intravitreal Bevacizumab Injection for Chronic, Atypical, or Recurrent Central Serous Chorioretinopathy

DC Field Value Language
dc.contributor.authorChung, YR-
dc.contributor.authorKim, JW-
dc.contributor.authorSong, JH-
dc.contributor.authorPark, A-
dc.contributor.authorKim, MH-
dc.date.accessioned2022-01-14T05:16:30Z-
dc.date.available2022-01-14T05:16:30Z-
dc.date.issued2019-
dc.identifier.issn0275-004X-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/19957-
dc.description.abstractPURPOSE: To evaluate intravitreal bevacizumab (IVB) injection efficacy for the treatment of chronic, atypical, or recurrent central serous chorioretinopathy (CSC).
METHODS: Clinical data from 77 eyes of 71 patients with chronic, atypical, or recurrent CSC treated with IVB were retrospectively analyzed. After initial 6-weekly IVB administration until no subretinal fluid remained at the fovea, additional as-needed IVBs were administered, based on optical coherence tomography findings. Best-corrected visual acuity and central retinal thickness (CRT) were analyzed at baseline and 3, 6, 9, and 12 months after initial IVB.
RESULTS: The significant improvement of baseline logarithm of minimum angle of resolution best-corrected visual acuity and CRT at 3 months (both P < 0.001) was maintained throughout the 12-month follow-up period. Best-corrected visual acuity improved significantly in patients with chronic and recurrent CSC, at all time points (all P < 0.05), but not in patients with atypical CSC. The CRT reduction was significant in all subgroups during the follow-up period (all P < 0.05). Definite leakage on initial fluorescein angiography correlated with improved reduction in CRT (P = 0.039).
CONCLUSION: As-needed optical coherence tomography-based IVB was effective for reducing CRT in patients with chronic, atypical, or recurrent CSC, and for vision improvement in chronic and recurrent CSC over the 1-year follow-up period.
-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAngiogenesis Inhibitors-
dc.subject.MESHBevacizumab-
dc.subject.MESHCentral Serous Chorioretinopathy-
dc.subject.MESHChoroid-
dc.subject.MESHChronic Disease-
dc.subject.MESHFemale-
dc.subject.MESHFluorescein Angiography-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHFundus Oculi-
dc.subject.MESHHumans-
dc.subject.MESHIntravitreal Injections-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHReceptors, Vascular Endothelial Growth Factor-
dc.subject.MESHRecurrence-
dc.subject.MESHRetina-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTime Factors-
dc.subject.MESHTomography, Optical Coherence-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHVisual Acuity-
dc.titleTwelve-Month Efficacy of Intravitreal Bevacizumab Injection for Chronic, Atypical, or Recurrent Central Serous Chorioretinopathy-
dc.typeArticle-
dc.identifier.pmid29077604-
dc.subject.keywordcentral retinal thickness-
dc.subject.keywordcentral serous chorioretinopathy-
dc.subject.keywordintravitreal bevacizumab-
dc.subject.keywordoptical coherence tomography-
dc.subject.keywordvisual acuity-
dc.contributor.affiliatedAuthorChung, YR-
dc.contributor.affiliatedAuthorSong, JH-
dc.type.localJournal Papers-
dc.identifier.doi10.1097/IAE.0000000000001917-
dc.citation.titleRetina (Philadelphia, Pa.)-
dc.citation.volume39-
dc.citation.number1-
dc.citation.date2019-
dc.citation.startPage134-
dc.citation.endPage142-
dc.identifier.bibliographicCitationRetina (Philadelphia, Pa.), 39(1). : 134-142, 2019-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1539-2864-
dc.relation.journalidJ00275004X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Ophthalmology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse